Amgen and Zhejiang Beta Pharma Co., Ltd. today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.
Showing posts with label Amgen and Zhejian Beta Pharma. Show all posts
Showing posts with label Amgen and Zhejian Beta Pharma. Show all posts
Subscribe to:
Posts (Atom)